The ultimate goal of EHAB is to accelerate the delivery of innovative health techniques and products, in the area of advanced therapies/regenerative medicine and biomaterials to citizens and patients who need it. This innovative healthcare should be affordable for all and improve the quality of life of patients. With Advanced Therapies & Biomaterials it will be possible to have more effective and efficient healthcare for lots of common diseases, like orthopedics, cancer or cardiovascular. Currently it is very hard to bring these techniques to the market and companies face many barriers, from production challenges to regulation. Joint action at an EU level can make the difference. Ecosystems can work together to overcome the barriers of the companies to catalyze and speed up the process of bringing innovative AT&B products to the market. The first step in creating this value chain is to capitalize and connect the assets with EU innovation ecosystems and lay the foundation for an excellent partnership from different European regions. EHAB’s Vision is thus to strengthen the European landscape in advanced therapies and biomaterials (AT&B) by building a European interconnected value chain and powerhouse to making cell and tissue related therapies available to all European citizens, seizing opportunities in key parts of the AT&B value chain, consolidating EU assets, notably SMEs and increasing its international competitiveness. EHAB’s Mission is to identify regional strengths, weaknesses, gaps and needs in a joint transregional AT&B value chain and to elaborate an action plan to strengthen the performance and capacity of the innovation ecosystems, their efficient interconnection and their alignment towards EU-level priorities, jointly tackling challenges at EU, national and regional level together with the quadruple helix stakeholders from the deeptech SME community, funding agencies, investors, academia, service providers, notified bodies, policy makers, patients.

“Bringing flexible organic electronics to pilot innovation scale” (PI-SCALE) is a highly needed response to bridge the gap which exists today between promising laboratory scale results of highly efficient flexible OLED modules and mass manufacturing of high value-added products. The project will integrate existing European infrastructures into a “European flexible OLED pilot line”, which will operate in an open access mode and serve customers from along the value chain with individual product designs, validation of upscaling concepts, and system-level flexible OLED integration. The Consortium will connect the most advanced pilot line facilities with the best material providers and equipment manufacturers, creating a service that will offer substantial numbers of flexible OLEDs that can meet efficiency, durability and cost requirements of end users. Together with end-users for various markets, such as automotive and designer luminaires, PI-SCALE will demonstrate the capabilities of this pilot line doing process optimisation for product demonstrators to enable cost efficient production and facilitate an effective market introduction. In addition PI-SCALE will include a number of outreach activities to actively engage and educate interested users and suppliers for flexible OLEDs in interactive product concept development. PI-SCALE will not only support the market acceptance of flexible OLED products, but it will also ensure that prototype ideas from European companies will have the possibility of reaching a semi-industrial scale in a very short time.